Smith & Nephew plc (LON:SN) Plans Dividend of $0.23

Smith & Nephew plc (LON:SN - Get Free Report) declared a dividend on Tuesday, February 25th, DividendData.Co.Uk reports. Shareholders of record on Thursday, March 27th will be paid a dividend of $0.23 per share on Wednesday, May 28th. This represents a yield of 1.61%. The ex-dividend date of this dividend is Thursday, March 27th. This is a 60.4% increase from Smith & Nephew's previous dividend of $0.14. The official announcement can be seen at this link.

Smith & Nephew Stock Performance

Shares of LON:SN traded up GBX 4 ($0.05) during mid-day trading on Friday, reaching GBX 1,071 ($13.86). 1,639,303 shares of the company's stock were exchanged, compared to its average volume of 343,671. The company has a quick ratio of 0.84, a current ratio of 2.51 and a debt-to-equity ratio of 70.22. The firm has a market cap of £11.74 billion, a price-to-earnings ratio of 38.56, a price-to-earnings-growth ratio of 0.46 and a beta of 0.62. The firm's fifty day simple moving average is GBX 1,070.03 and its two-hundred day simple moving average is GBX 1,051.48.

Insider Transactions at Smith & Nephew

In other news, insider Sybella Stanley acquired 3,810 shares of the firm's stock in a transaction dated Wednesday, March 26th. The stock was purchased at an average price of GBX 1,101 ($14.25) per share, for a total transaction of £41,948.10 ($54,294.72). Insiders own 0.19% of the company's stock.

Analysts Set New Price Targets

Separately, JPMorgan Chase & Co. reissued an "overweight" rating and issued a GBX 1,180 ($15.27) price target on shares of Smith & Nephew in a research note on Tuesday, January 14th.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.